Search
Results
showing 1-10 of 2318
Global Health Watch: Billions in Question, NIH + America First Plans, WHO + Global Fund Leadership & PPPR Rejection
October 2026
The US fiscal year ended this week amid questions about the billion dollars in Congressionally-appropriated foreign assistance, while new strategies for HIV research at the National Institutes of Health (NIH) and the America First Global Health strategy theoretically move into implementation phases. Also, the Global Fund announced five candidates for its Executive Director, and six candidates were shared as possible leaders of the World Health Organization (WHO), just after the US rejected the UN pandemic preparedness declaration at the end of last week.
HIV Prevention Pipeline: Products to Watch
September 2026
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
ARV-Based and Multipurpose Prevention Technology R&D Pipeline
September 2026
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
At A Glance: The MPT R&D Pipeline
September 2026
This graphic shows the status of products in development.
Lenacapavir Regulatory Approval
September 2026
Regulatory approvals, pending decisions, and appeals as of September 2026.
Global Health Watch: White House Drops NIH Review Plan, NIAID Reorg Moves Fwd, Prep for Generic LEN Access, Accra Reset
September 2026
There is no shortage of global health news this week. Against the backdrop of the UN General Assembly (UNGA 81), this issue covers efforts to reshape the global health architecture through the Accra Reset, proposed and withdrawn Executive Orders affecting NIH grant making, NIAID restructuring developments, and preparations to expand access to generic lenacapavir for PrEP.
Artificial Intelligence in the HIV response: All the good stuff from AIDS2026
September 2026
An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the potential of AI to support HIV testing and prevention, including PrEP, and improve linkages to care and services, particularly in sub-Saharan Africa. “AI is becoming a new front door to HIV services,” he writes, but the analysis also shows that while most of the research was focused on feasibility and pilot implementation of AI, a significant evidence gap around health outcomes, as well as privacy, community engagement, and governance remains. He concludes that: AI is working, but trust is what makes or breaks the product; specialized tools beat generics; human-in-the-loop is becoming standard; the field needs to move from pilots to proof of outcomes; and scale depends on systems, not just models.
AVAC Comment on Proposed Reorganization of the National Institutes of Allergy and Infectious Diseases (NIAID)
September 2026
In response to the National Institute of Health’s (NIH) proposed reorganization of the National Institutes of Allergy and Infectious Diseases (NIAID), AVAC submitted comment to the Office of the Director of the NIH. Citing concerns of dismantling a currently unified trial oversight and support system, disruptions to trial site readiness and impacts on community engagement, and delays in funding and clinical trials, AVAC urged NIH leadership to meaningfully consider the recommendations of AVAC and many allied public health partners on the proposed restructuring.
Global Health Watch: LEN Access Pathways, NIAID Reorganization, Global Fund Report, NIH Lawsuit
September 2026
This week’s issue covers developments shaping access to HIV prevention and the future of US biomedical research, including new pathways to accelerate access to lenacapavir for HIV PrEP, calls for greater transparency around a proposed NIAID restructuring, and a new lawsuit challenging NIH’s screening of research grants. With today as the final day to comment on the NIAID proposal, make your voice heard. And read on for a provocative Lancet commentary on the challenges of trying to reform global health architecture.
showing 1-10 of 2318